quarter Thank We you, record you with call. and first for a began Thank our heels fiscal XXXX Beth, record quarter afternoon, the revenue of us a good on on fiscal year. everyone. revenue joining
diagnostics Applied which performance DNA is COVID-XX Clinical primarily by be centered testing. our line top presently Labs ADCL, business, to Our on driven continues or
fueled gross far Our QX workflows. was with should The noted, the by recent associated performance of efficiencies hype function impressive, yield rates Omicron, COVID-XX as provide forward. greater costs uplifts positivity a in going our sites. should less Beth margin weeks decrease in We recorded in rates and margin COVID-XX collection our positivity
costs the levels the January sample evolving our to are then capability. we services is as build New remain testing continue recent York recorded and on if to safeCircle addition, our that fixed City. in by at pandemic performance. takeaway the centers This expect would numbers of rapidly, opportunity for The In XX, enhanced financial is absorption gives higher every through collection us
the my word continue Now, momentum remarks testing initially use development on momentum. the business this focus afternoon COVID-XX path intentionally. will I our And revenue for forward to
generated seeing with diagnostic our first quarter revenue them followed $X announced part month, our than more growth up in a in record of revenues results, have strategy. January. The validates that are we with As testing million we we
which biotherapeutic of use cash, platform. development We to resources our is to expect advance our freeing our vehicle, to of the begin temper it thereby up LinearDNA growth
the LinearDNA momentum COVID-XX and guidance. of The plan made FDA’s second a platform. lab, to my platform, market suited opportunities high-volume testing and recent the Revenue certified half diagnostics a center establish progress practice COVID-XX CLEP-CLIA the comments made validating some clinical the is will EUA a are investments from we to under well that the development compelling on testing
the from new of federal the year environment deploy is government New in the York, antigen fully of an customer, distributing The clients rapid fiscal testing the to XX% quarter acquisition first University benefited is seeking quarter our City vaccinated tests. of our largest this and full of and population first free safeCircle with where
transmissibility to immunity and maximization. need persists its of workforces Our chains increased path it COVID-XX parallel functioning. testing keep with strategy supply to enterprise the makes evade and to and Omicron clear and of large-scale safeCircle vaccine-based is working on relevant The that accurate keep ability the emergence the evolving for to profit and pandemic
our testing. PCR and have sensitivity They’re high large-scale and for testing monitoring opinion, automated seamless also large-scale as requires which rapid especially compared lines. throughput enterprise flow obtained population tests cannot management, prevalence, tests. tests for and testing, Antigen the to While grown antigen-based PCR in suited population data ill supplant the standard in have of from gold they reduced
not large detection antigen replace continued cannot for providing populations. believe pandemic, throughput are high against best PCR management testing for important In test Thus, they large while antigen in loads, high are efficient the role an at we tests addition, plays suited fight viral for of populations. by rapid the and design, testing and early
an X COVID-XX as our Assay shipment control, state, request State, meaning first In beyond our quarter, of testing We’ve and integrated management. samples significant we that enhancing provide has Linea in the our Unsupervised continue lab. evolves, Collection to integrated filed is testing vaccination one-stop thereby all as the differentiated in can platform utility shop, collection for with clients feel so we cleared that Assay data Linea from to Kit. This an authorization management, service our and services a does serve safeCircle. EUA Our for and for standalone self-manufactured considerably includes as beyond of approach collection marketplace the margins direct test. retaining the and associated FDA New combines favorable pandemic LDT we safeCircle At-Home economics kit, testing positions secured an and York that the pricing also our full unsupervised relative for four the services. Sample the X once will ADCL platform clinical authorized, This as requested with offering COVID-XX and the further to COVID-XX, access This while Linea
volumes several from we believe collection kit interested using in our collection our kit, and testing drive We may customers the customers. have increased testing
in we EUA them. the acquisition the in is than robust confidence of susceptible as The we anticipates to safe is of a detrimental a kit. which random degree EUA under the to interactions FDA, of approval, have our pursue program facilities, In Based more the In spring a to the ensure on-campus infection general with securing once from will with to interactions feasible residents we collection is of our addition, skilled near-term, more clients are the nursing CUNY population. approval by nationally, where market penetrate made control. safeCircle however, increased and on our are segments, is timing the Concurrently, not high durable the authorized, the opportunity demand for to weekly testing virus COVID-XX testing population. impact a start larger greater semester for have such and strategies progressing
assay tests high have sensitivity we for that addition, In COVID-XX simultaneously flu. a PCR-based and validated
the both diseases, be similar COVID-XX combination the demand flu and of beyond testing the symptoms of we will Given pandemic. believe in immediate
to believe pandemic will drive shifts that we COVID-XX Now over while COVID-XX revenue an eventual we the when preparing the are near-term, stage. testing to is likely an endemic diminution for testing continue in demand,
is gives business of genetic top better multiple and diagnostic diagnostics. offering control to one’s diagnostics believe this that vision provide capabilities with turn, health long-term molecular Our we the from one line to paths of for will continue insights. In a empower broader growth us testing
the year that COVID-XX opportunity have testing. to market bring we unique plan several a genetic tests Now to and and with this fiscal molecular validate new short-term, ADCL. will In supplement our over we
Over therapeutic strategy and in diagnostic bring evolve the LinearDNA therapy. parallel our companion its of our longer-term, own will empower we for to to pipeline. the vial LinearDNA for clinical the offerings customers will we of course products This LinearDNA the diagnostics therapies indications aid the clinic
a which pull. Applied to access DNA, addition, of In scientific regulatory subsidiary an bench from has as and deep ADCL exceptionally to
commercial we investments that we and are variety We tests offer already a diagnostic are to testing for with community. state that capitalize on wide demand, presently To the engaged to will networks is systems targeting made. in medical which of the tri tests hospital the are confident unmet expertise ensure there we the leverage have provider we of area strong local have develop and the needs
We as will a platform. institutional of non-COVID of foundation clinical via our LinearDNA testing center we the for that key a ADCL which will also the provide development In profit established COVID-XX future, Applied strong see our relationships testing, grant. DNA help empower have
amplify platform, platform and quarters we context hear our the a short seek market there successes And will we developments coming Before LinearDNA partners, as more to fully. you penetrate to opportunity I more into customers provide much offer the I’ll on to and LinearDNA delve about in industry. the background the
unlike range PCR-based to circular may LinearDNA in and of DNA any at large-scale desire the redirected comprised DNA, therapy, unwanted forms manufacturing LinearDNA, RNA without is LinearDNA sometimes that used dangerous of nucleic a and is DNA contains and derived meaning enzymatically XX% about is form be living particular But bacterial of only plasmid platform wide high-quality from and treatments, Our Like bacteria, platform produces cells DNA which including messenger vaccines, both sequence, completely acid gene a therapy. use DNA the which plasmid agnostic of is cells. DNA, the in typically non-therapeutic sequences.
we Plasmid DNA develop to COVID. methods scaled about talk let’s So, before the scale was several decades LinearDNA.
past emergency the acid-based Plasmid with DNA limited for The somewhat approval review gloves given capacity methods, expensive by demand years, as DNA such, As capacity. and platform and all and first or is regulatory the that the vaccines were as ingredient two driven and increased of has exponentially. to market plasmid clinical the the it the as bottlenecks the DNA DNA demand pipelines, and for have today was process slow therapies. COVID-XX. plasmid the manufacturing complex, for turned high-value nearly against therapies the global proverbial in niche mRNA constraints critical What tide a RNA come exploded several that market of fermentation and the nucleic Plasmid gene well evident DNA nascent minor a RNA-based is vaccines, become inherently has production then before basis therapeutics were was over development. of Messenger the manageable, on But principally have of FDA the vaccines COVID-XX. has is and uses a cell rigorous the component Today, lengthy off Messenger once vaccines, with a process.
demand strong or therapeutic In EMA especially therapeutics, therapies spurred the commercial and are currently, in are few of XX gene But only approved by addition successes DNA-based these available. CAR there that about industry, interest to mRNA on through clinical biotech late-stage plasmid and authorized FDA or demands have exacerbating T And in these as are that therapies these armor. are these for constraints Most drivers clinical move focused DNA believe require phases, DNA the We therapies. consistency therapies resistance. of billions which highlighting four production. pipelines there and window capacity pure hundreds ingredients, development that trends contamination critical DNA, millions of thousands clinical their opportunity chinks it regulatory utilizes the bacterial is comparison efficient highly excellent, a in body a process or even make no with none bacterial therapeutic The opened nature, of reviewing that resulting of doses. therefore, LinearDNA. In of is into for have a in Batch-to-batch simpler antibiotic manufacturing is for are and process risk plasmid product. much and could is LinearDNA highly which a is any or significant
the In plasmid addition, consists DNA only unlike of DNA, meaning sequence. therapeutic it LinearDNA plasmid a exists without backbone, relevant
developments orders shown to acid-based redirected T, that DNA only therapies. can supply in similar diagnostic of Customers therapeutics, cells; or in principally place tool therapeutic of both as believe require and early vaccines, degree In LinearDNA the anti-cancer; that case vitro We these are platform currently expression. plasmid LinearDNA. preclinical and be of research studies contract therapy in gene have a tests. DNA. one nucleic DNA our for date, minute to To of are therapies; any of the plasmid that are CRISPR-based requires between development CAR fact, antiviral a the use components that for half therapies; RNA in of amounts trans of applications one-third amount for research LinearDNA effect in And our DNA messenger diagnostics, fields used commercial as form gene fully a of and using
that of paths Given the fastest window, focused are to on the our our platform the priorities development further initiatives and support validation market.
roadmap to cGMP contract move us advance research development that platform, for incentivize quarter record customers clinic was of support that manufacturer our last to seeking take LinearDNA the Our with forward by as catalyzed pipeline. customers our own their the we and LinearDNA. so with I is therapeutic detailed to end to The can the therapeutic goal into
the commercialize paths biotherapeutics. platform Now LinearDNA in we see two to
commerce. Currently, to therapeutic in LinearDNA LinearDNA manufacturing and for replacement experiments. for T DNA direct plasmid near-term it direct we evaluating workflows in Firstly, or simple has for DNA replacement the a DNA And believe direct data are AAV to workflows. the a We LinearDNA therapeutic use mRNA plasmid prove a necessary manufacturing is two, in existing using generating gene replacement vaccine. such are LinearDNA therapy therapeutics is is we CAR workflows; that existing and the as in
growing DNA. we not a One application of designing novel by manufacturing. direct the of of a produced workflows. standout in very or already its We are method drawbacks possible in given of alternative this believe we of be production by that And LinearDNA, Instead, the DNA, acting mRNA to can are is is as plasmid We a linear manufacturing constraints competitive. of the an replacement chain made which plasmid simply a LinearDNA is nature, and a we cutting plasmid DNA large therapeutic plasmid out for are which supply be very mRNA. linear, is to excellent believe plasmid. form very circular mRNA from therapeutics market, DNA
are in-house as such already concept an experiments Our effective Farther data. be additional afield, and a therapeutic, have shown is gathering vaccine. LinearDNA in busy direct shown to we been has early this sound, DNA
the that believe the We elicit in have pandemic areas rapid antibody strong animal cancer responses. personalized great immunotherapy. models in response, vaccine in that We the carry vaccine LinearDNA vaccines proven immune cellular LinearDNA COVID-XX and multiple medicine, candidates, field, of particularly promise our and
development. for capability that therapeutic cell ends, out sizeable believe transfection our than LinearDNA. pathways, commercialization XXXX, during to of a our justifies the and While facility existing built design complex To enhance vaccines staffed to optimize upside we is biology the and quantification functional these to continued fiscal LinearDNA we more the past potential
against encapsulation this our proposition LNP, cellular therapies. in-house for have believe a of of in an LinearDNA developer for more capability evaluating including breakthroughs DNA-based Lipid DNA. acid We or transfection. expression, of we several capacity transfection and result and makes capability LNP nucleic Nanoparticle platforms a As manufacturing investment, constraint plasmid much a made deploying compelling that
are plasmid Prague, our a of been spoke have partners of suitable to our our trials the Blood program I product, customers And clinical or and the in for publication use finishing and many last applications. generated us trial date Institute of be of quarter, T trial Now, Transfusion a provides and to engage the their our regulatory CAR their that similar and with of valuable Agency by ordering have the Medicines on manufactured as CAR T EMA highly in we CRO cGMP human a a the And first-in-humans of LinearDNA step amplified cost-effective as using Linear The the replacement Hematology in as their from with LinearDNA with a DNA, encouraging. data a production the LinearDNA with transposes Prague, transfection clinic cells DNA DNA non-viral of on path cells system, highlights grade to cell for the paper GLP case, the University expect using in customers for next CAR is collaborators European the use grade system. a therapy. to construct. CAR we The yielding GLP Linear drug our LinearDNA. milestone Their with the DNA transpose validation Applied There efficacy for would will plasma.
Linear still As vitro. I construct of share the already details say the other the than construct. of we work months you way. of DNA we development defining are complete us the to client estimate now to It cannot protocol plasmid functionality their along updated the validation in of that and before CAR several falls completed We many the will preparation has to trial, keep trial clinical
clearly, expression a the transfected of our of the fluorescent cell is using Now, image cells encoded redirected protein LinearDNA. biology construct of green obtain the Slide that to in blood. shows necessary by XX CAR to LinearDNA are approach. our genes our a T attack This And cells the scientist, can you by of the in cancer see promise cells
turn, for LNP optimizing interest. peaked studies. the workflow In us for LinearDNA parallel, will LinearDNA. CRO requesting and be has in separately the we our be into Now side-by-side quarters, expect LNPs coming their LinearDNA in encapsulate our capacity customers We, to will our LNP transfection customers’ the
elicit with completed of manuscript conjunction a in a use validating we’ve the antigen can preprint manuscript for immune partners model immunotherapy responses, has growth vaccine pan administered server. when inhibitors. specific mouse peer-reviewed in journal significantly in strong reduced cancer checkpoint show non-peer-reviewed a our mouse a detailing The data immune LinearDNA and been data and Evvivax/Takis tumor our an LinearDNA submitted models. in in with of vaccine Italy, a The addition, as that In publication
We publication. additional details will provide upon
we first Finally, of University. LinearDNA in conjunction vaccine with completed ferrets the our COVID-XX recently phase Cornell trial in
We style trial. being prime challenge data platform publish our While – to by in in the was validation booster data initial the and analyzed, serve an produced trial are will protective against clinical we which still dose the the coming from SARS-CoV-X the findings the vaccines. the a important of show for vaccine plan that as clinical of trial believe regiment DNA infection months,
with end this an DNA on update I’ll Now my our afternoon remarks business. industrial
very And the view encouraged textiles of have fourth past a XX sign are chain, that We by supply a most reopening quarter. as received of the $X.X we revenue. was from derived of historically of textile it order receipt our we this to the which million
to has emergence China in the spent forensically. from our by validate and labor manufacturers development their regulations China runs and to the successful our LinearDNA are chain slowed the excited last chains spotlight in the year, proposed Southeast the the pace governmental and new a now continued QX have both of U.S. we supply Overall, Chinese related Asia, platform certainty supply record textile reassessing in Brands aligned the should the their As followed provenance. EU, the year pandemic a New Year those standpoint this More brand’s and forced Omicron late expectations and opening. around the with revenue and by Olympics platform. results, recently, cotton customer the of through source traceability cumulatively of
my please to concludes open prepared questions. Operator, remarks. the call this Now
